Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an ...
Curanex Pharmaceuticals, Inc. CURX on Thursday said it is expanding its drug development pipeline. Pipeline Expansion Adds ...
The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...
Dealbreaker on MSN
Gilead’s pipeline strategy takes shape with $3B acquisition of cancer biotech Tubulis
Analysts say the Tubulis platform technologies that yielded these ADCs could also help Gilead develop drugs in other ...
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight The severe asthma clinical trial analysis ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
Novo Nordisk's CagriSema failed to achieve non-inferior weight loss versus tirzepatide in the pivotal REDEFINE-4 study. See ...
DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...
OPKO Health is refocusing on drug development, with most pipeline assets in early stages and limited near-term catalysts.
Curanex believes the combination of major unmet need, limited treatment options and growing clinical recognition supports a ...
Demand for these drugs is high, and analysts predict the market will reach nearly $100 billion by the end of the decade. And ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results